Inventiva SACA

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

14 янв 2022 02:00:00 Источник Nasdaq GlobeNewswire

Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference

16 дек 2021 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor

06 дек 2021 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva reports 2021 Third Quarter Financial Information

10 ноя 2021 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021  

03 ноя 2021 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces participation at several conferences in November 2021

29 окт 2021 09:29:01 Источник Nasdaq GlobeNewswire

Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes

27 окт 2021 16:00:00 Источник Nasdaq GlobeNewswire

The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH

20 окт 2021 17:07:18 Источник Nasdaq GlobeNewswire

Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021

18 окт 2021 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces participation at several investor conferences in October 2021

28 сен 2021 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva completes sale of $30 million through its ATM program to existing and new specialized institutional investors

23 сен 2021 02:45:00 Источник Nasdaq GlobeNewswire

Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis

21 сен 2021 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva reports 2021 first half financial results and provides a corporate update

20 сен 2021 16:10:00 Источник Nasdaq GlobeNewswire

Inventiva announces major recruitments to accelerate the development of lanifibranor in NASH

16 сен 2021 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva’s 2021 First-Half Financial Results Presentation

10 сен 2021 09:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH

08 сен 2021 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces participation at several investor conferences in September 2021  

30 авг 2021 16:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces the implementation of an At-The-Market program in the United States

02 авг 2021 17:00:00 Источник Nasdaq GlobeNewswire

Inventiva Reports First-Half of 2021 Financial Information

28 июл 2021 16:00:00 Источник Nasdaq GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

22 июл 2021 10:00:00 Источник Nasdaq GlobeNewswire